Oral versus Intravenous Antibiotic treatment for Osteomyelitis in Adults: A Systematic Review and Meta-Analysis
- VernacularTitle:Oral versus Intravenous Antibiotic treatment for Osteomyelitis in Adults: A Systematic Review and Meta-Analysis
- Author:
Ramon Jr B. Larrazabal
1
;
Harold Henrison C. Chiu
2
;
Marlon S. Arcegono
3
;
Cybele Lara R. Abad
3
Author Information
1. Department of Medicine, Philippine General Hospital, University of the Philippines Manila, Taft Avenue, Ermita, Manila
2. Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Philippine General Hospital, University of the Philippines Manila, Taft Avenue, Ermita, Manila
3. Division of Infectious Diseases, Department of Medicine, Philippine General Hospital, University of the Philippines Manila, Taft Avenue, Ermita, Manila
- Publication Type:Journal Article
- Keywords:
Oral;
Intravenous;
Parenteral;
Osteomyelitis;
Randomized Control Trials
- MeSH:
Osteomyelitis;
Administration, Intravenous ' Parenteral Nutrition
- From:
Philippine Journal of Internal Medicine
2020;58(4):146-153
- CountryPhilippines
- Language:English
-
Abstract:
BACKGROUND: The worldwide incidence of osteomyelitis is approximately 21.8 cases per 100,000 person-years. The cornerstone of treatment is prolonged (4-6 weeks) intravenous antibiotic administration. This entails additional cost, inconvenience, and added manpower from the healthcare system. Thus, studies have explored the possible use of oral antibiotics as alternatives to improve patient compliance and reduce costs. Our meta-analysis aimed to compare the efficacy of oral versus intravenous antibiotics in treating adult patients with osteomyelitis.
MATERIALS AND METHODS: Electronic databases (PubMed, Medline, EMBASE, Cochrane Central Register of Controlled Trials, Google Scholar, and Research Gate) from 1966 to April 2020 were searched using the terms “oral antibiotics”, “osteomyelitis”, “randomized controlled trial”. Only studies that directly compared oral versus intravenous antibiotics and confirmed osteomyelitis through biopsy and/or imaging were included. Primary outcome is remission (resolution of symptoms with no relapse and bacteriologic eradication); secondary outcomes, (a) relapse (persistence of the pathogen after treatment) and (b) adverse events. The validity of included studies was assessed using the Cochrane Handbook for Systematic Reviews of Interventions. We performed a random-effects model in Review Manager Version 5.3 with 95% confidence interval. The I 2 test was used to assess heterogeneity.
RESULTS: Seven of 89 trials comprised of 1,282 patients were included in the final analysis. All studies included patients with osteomyelitis of the lower extremities. Oral antibiotics used were Ciprofloxacin, Ofloxacin, and Co-trimoxazole; intravenous antibiotics used were deemed appropriate by the infectious disease specialist. Patients were only given either oral or intravenous antibiotics. Results showed an 8% increase in remission rates [RR 1.08 (0.81 to 1.44, 95% CI, Z = 0.52, p=0.60)] with no heterogeneity (I2 = 0%) in the intravenous antibiotics group. However, this was not statistically significant. Furthermore, there was a 62% decrease in relapse rates in the intravenous antibiotics group [RR 1.62 (0.85 to 3.07, 95% CI, Z = 1.47, p = 0.14)] with no heterogeneity (I2 = 0%) but was not statistically significant.
CONCLUSION: Oral are comparable to intravenous antibiotics in treating osteomyelitis in terms of remission and relapse rates. However, larger and double-blinded trials should be done to generate more robust data to validate these claims.
- Full text:7-OralvsIV.pdf
